TIL: Instil Bio, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 76.62
Enterprise Value ($M) 148.66
Book Value ($M) 234.02
Book Value / Share 35.98
Price / Book 0.33
NCAV ($M) 89.38
NCAV / Share 13.74
Price / NCAV 0.86

Profitability (mra)
Return on Invested Capital (ROIC) -0.62
Return on Assets (ROA) -0.41
Return on Equity (ROE) -0.54

Liquidity (mrq)
Quick Ratio 14.53
Current Ratio 14.53

Balance Sheet (mrq) ($M)
Current Assets 195.63
Assets 340.27
Liabilities 106.25
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
04-10 13G/A Fmr Llc 0.03 -99.63
2023-02-14 13G/A Ra Capital Management, L.p. 0.00 -100.00

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2023-11-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT
2023-11-13 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUA
2023-08-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO S
2023-05-11 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO
2023-03-31 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTI

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-02-23 1,057 8,776 12.04
2024-02-22 1,990 13,781 14.44
2024-02-21 3,769 18,884 19.96
2024-02-20 3,004 25,748 11.67

(click for more detail)

Similar Companies
TGTX – TG Therapeutics, Inc. THAR – Tharimmune, Inc.
THTX – Theratechnologies Inc. TLSA – Tiziana Life Sciences Ltd
TNXP – Tonix Pharmaceuticals Holding Corp.


Financial data and stock pages provided by
Fintel.io